Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 49.25% | 22.54% | 9.20% | 24.91% | -43.18% |
| Total Depreciation and Amortization | -17.70% | -25.65% | -19.05% | -18.16% | 146.16% |
| Total Amortization of Deferred Charges | 2.44% | -2.38% | 0.00% | 0.00% | -69.17% |
| Total Other Non-Cash Items | -36.41% | -88.70% | 18.48% | -9.04% | -27.63% |
| Change in Net Operating Assets | -234.84% | 45.53% | -106.95% | -1,182.47% | 111.30% |
| Cash from Operations | 10.31% | -9.98% | 9.38% | -12.36% | 69.46% |
| Capital Expenditure | -- | -6,792.11% | 74.64% | 99.96% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 907.02% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.65% | 121.47% | 113.12% | 16,542.61% | -1,794.18% |
| Cash from Investing | 66.90% | 117.35% | 111.64% | 826.78% | -613.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 90.82% | 87.68% | 88.00% |
| Issuance of Common Stock | -34.61% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 31.83% | -- | -- | -- | -33.96% |
| Cash from Financing | -34.55% | 16,925.51% | 90.82% | 4,110.84% | 2,237.20% |
| Foreign Exchange rate Adjustments | -93.55% | -76.88% | -274.32% | -108.22% | 365.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 51.33% | 83.99% | 90.53% | 199.31% | 17.35% |